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Defensins are cationic antimicrobial peptides that contribute to regulation of host cell function also.
Here, we report on the regulation of cell death by Human Defensin 5, the major antimicrobial pep-
tide of ileal Paneth cells. We ﬁnd that Human Defensin 5-mediated cellular effects depend on func-
tional expression of Tumor Necrosis Factor receptors and downstream mediators of TNF signaling.
Our data indicate the involvement of interactions between Human Defensin 5 and the extra-cellular
domain of Tumor Necrosis Factor receptor 1. Human Defensin-5 also induces apoptosis intrinsically
by targeting the mitochondrial membrane.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Defensins are endogenous peptides produced by certain leuko-
cytes and epithelial cells [1–3]. These peptides demonstrate anti-
microbial, antiviral, toxin-neutralizing and immuno-modulatory
properties [3–7]. They are small, cationic, beta-sheet, tri-disul-
phide peptides [8,9] and, in humans, comprise genetically distinct
alpha and beta subfamilies that evolved from a common ancestral
gene [10,11]. In humans, six a-defensins have been identiﬁed to
date, termed Human Neutrophil Peptide 1–4 and Human Defensin
5 and -6. Human Neutrophil Peptides (HNP1-3) differ from each
other by an N- terminal amino acid residue and were originally iso-
lated from azurophilic granules of neutrophils [12,13]. HNP4, dis-
similar to HNP1-3 and much less abundant, was found later in
neutrophils [14–16], followed by the discovery of the two enteric
a-defensins (HD-5 and HD-6), expressed in Paneth cell of the small
intestine [17,18].
Defensins also act in adaptive immunity by serving as chemoat-
tractants and activators of immune cells [2,19]. For example, HNP-
2 and hBD2 are chemotactic to CD4+/CD45RA+ naive T cells, CD8+ T
cells, immature dendritic cells and monocytes/macrophages
[20–22]. For hBD2, chemotaxis of immature dendritic cells and
memory T cells results from its direct binding and activation ofthe chemokine receptor CCR6 who’s only known chemokine-ligand
is MIP-3a [23]. Members of the b-defensin family have been fur-
ther shown to interact with Toll-Like Receptor 4 [24] and more re-
cently the melanocortin 1 receptor, causing black coat color in
domestic dogs [25]. For most defensins, however, their cognate
receptors in adaptive immune responses have yet to be identiﬁed.
The only member of the human a-defensin family to date with re-
ported receptor interactions is HNP1. Interaction of HNP-1 with the
purinergic receptor P2Y on airway epithelial cells has been re-
ported [26]. In addition, HNP-1 was shown to inhibit monocyte dif-
ferentiation, partly due to interactions with the P2Y6 receptor [27].
More recently, the activation of macrophages by HNP-1 was shown
to be insensitive to pertussis toxin, as well as independent of puri-
nergic receptors, Toll-like Receptor and CD18 signaling [28] sug-
gesting these effects may be cell type dependent.
We previously reported that HD-5 signaling is MAPK- and NF-
jB-dependent and that HD-5 signals together with TNFa in a syn-
ergistic fashion [29,30]. Here, we report on the involvement of
TNFa receptors on HD-5-mediated cellular effects. We ﬁrst exam-
ined the effects of HD-5 on murine cells lacking TNF receptor genes
(TNFR1 and 2 knockout). More detailed involvement of receptors
was examined in cells that express human TNF receptors carrying
deletions or mutations in their extracellular domains. Cell viability,
apoptosis, signaling, caspase activation and mitochondrial mem-
brane activity was measured in cells deleted for TNF receptor
downstream effectors RIP1 kinase and caspase-8.
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2.1. Solid phase peptide synthesis
Chemical synthesis of HD-5 was carried out as described [31].
FAM-HD-5, a ﬂuorescein-labeled form of HD-5 was prepared as fol-
lows: N-hydroxysuccinimide-activated FAM was added to HD-5
peptide at 3:1 molar ratio in 50% Di-Methyl Formamide (DMF),
0.1 M HEPES pH 7.3 at a ﬁnal peptide concentration of 8 mg/ml.
The reaction was carried out for 2 h and labeled peptide was re-
puriﬁed by HPLC. The molecular mass of the peptides was veriﬁed
by electrospray ionization mass spectrometry (ESI-MS) as de-
scribed [31].
2.2. Cell culture
The Jurkat and the capsase-8 deﬁcient Jurkat cell line I9.2 were
obtained from the American Type and Tissue Culture (ATTC). The
RIP1-deﬁcient Jurkat cell line termed TM2 [32] was generously
provided by Dr. Ting (Mount Sinai Hospital, New York). Wild-type
and TNF receptor double knockout murine macrophages [33] were
generously provided by Dr. Aggarwal (University of Texas MD
Anderson Cancer Center). TNF receptor 1 and 2 double knockout
murine macrophages expressing the extra-cellular domain of
TNFR1 fused to FAS (TNFR1-FAS), the extra-cellular domain of
TNFR1 with the ﬁrst cysteine-rich domain deleted (DTNFR1-FAS)
and the extra-cellular domain with the cysteine-rich domain of
TNFR2 replacing that of TNFR1 (CRD1TNFR2-TNFR1-FAS) were gen-
erously provided by Dr. Scheurich (University of Stuttgart,
Germany [34]). Jurkat TM2 cells were passaged in Iscove’s modi-
ﬁed Dulbecco’s medium with 10% iron- supplemented calf serum,
0.25 mg/ml xanthine, 0.1 mM hypoxanthine, and 5 lg/ml myco-
phenolic acid. For all experiments, the wild-type and KO12 murine
macrophages and the Jurkat cell lines were maintained in RPMI
1640 medium (Gibco), supplemented with 10% FBS (Valley Bio-
medical, Winchester, VA), 2 mM L-glutamine (Quality Biological,
Gaithersburg, MD), 20 mM HEPES, 1  non-essential amino acids,
1 mM sodium pyruvate and 5% Penicillin/Streptomycin (Sigma)
in a humidiﬁed incubator at 37 C with 5% CO2. The TNFR1-FAS,
DTNFR1-FAS and CRD1TNFR2-TNFR1-FAS cells were maintained
with 5% FBS RPMI 1640 medium (Gibco), supplemented with 10%
FBS (Valley Biomedical, Winchester, VA), 2 mM L-glutamine (Qual-
ity Biological, Gaithersburg, MD), 20 mM HEPES, 1  non-essential
amino acids, 1 mM sodium pyruvate and 5% Penicillin/Streptomy-
cin (Sigma) in a humidiﬁed incubator at 37 C with 5% CO2.
2.3. Cell viability
The effect of defensin peptides on cell viability was assessed by
measuring the mitochondrial activity using MTS assays according
to the manufacturer’s instructions (Cell Titer 96 proliferation assay,
Promega). The cells were cultured in 96-well plates in the presence
of serum, washed once in culture medium without serum and sub-
sequently exposed to the peptides at the indicated concentration
for 16 h. The number of viable cells was determined by measuring
the absorbance at 450 nm on a microplate reader (Molecular
Devices).2.4. Evaluation of cytokine secretion
Jurkat cells were gently washed in serum-free medium and sub-
sequently plated in 96-well plates at 1  106 cells/ml in serum-free
medium. Cells were incubated for 16 h in the presence of HD-5
peptide at indicated concentrations. Culture supernatants werecollected for measurement of IL-8 using the Luminex-100 system
(Bio-Rad).
2.5. Apoptotic assays
Caspase-8 and caspase-9 activity in cell lysates were measured
using the ﬂuorogenic Ac-VETD-AMC peptide substrate (Sigma) or
the caspase-9 colorimetric kit (Invitrogen) according to manufac-
turer’s instructions. For these experiments, cells were cultured on
6-well tissue culture plates. Cells were washed with serum-free
medium and incubated for 16 h in serum-free medium containing
the peptides at ﬁnal concentrations as indicated. Following incuba-
tion, cells were washed with PBS and lysed in 200 ll of lysis buffer
(20 mM HEPES, 50 mM NaCl, pH 7.2 10 mM DTT containing 1%
CHAPS, 1 mM EDTA, 2 mM PMSF, leupeptin (10 lg/ml; Sigma)
and pepstatin A (10 lg/ml; Sigma) for 30 min on ice. After centri-
fugation (7000g, 10 min), the protein concentration of the
supernatant was determined using the BCA Protein assay reagent
(Bio-Rad). Subsequently, 20 lg of each sample was diluted to a ﬁ-
nal volume of 200 ll in assay buffer (20 mM HEPES, 50 mM NaCl,
pH 7.2 10 mM DTT, 0.1% CHAPS containing either the caspase-8
or caspase-9 substrate) in a 96-well plate. For caspase-8, ﬂuores-
cence was determined (excitation 405 nm, emission 538 nm) with
a Cary Eclipse ﬂuorescence spectrophotometer (Varian, Palo Alto,
CA). For caspase-9 activity, absorbance at 450 nm was measured.
2.6. Flow cytometry
Apoptosis in Jurkat cells was determined using the Annexin-
FITC apoptosis kit from Calbiochem according to manufacturer
protocol. Jurkat, Jurkat I9.2 or Jurkat TM2 cells (2  105 cells/ml)
were exposed to peptide in serum-free medium for 16 h and
subsequently analyzed by ﬂow cytometry (FACSCalibur, BD
Biosciences).
2.7. Confocal microscopy
Jurkat cells or murine macrophages were cultured on collagen-
coated cover glass slips (Mylteni Biotech) as described above for 24
in the presence of serum. The cells were gently washed twice in
serum-free medium and incubated at 4 C for 90 min. Subse-
quently, cells were exposed to FAM-HD5 (10 lg/ml) and either
ﬁxed immediately with 4% formaldehyde or further incubated at
37 C for 30 min before ﬁxation. The localization and visualization
of FAM-HD5 on the cells was analyzed using ﬂuorescence confocal
microscopy (Zeiss).
2.8. Cell membrane integrity and ATP release assays
Membrane integrity and ATP release was determined using the
mitochondrial ToxGlo assay (Promega) according to manufac-
turer’s instructions. For these experiments, cells were cultured on
96-well tissue culture plates, gently washed with serum-free med-
ium and subsequently incubated for 16 h in serum-free medium
containing the peptides at ﬁnal concentrations as indicated.
3. Results
3.1. Interaction of HD-5 with cells of the host
To study the functional interaction between HD-5 and TNF
receptor-mediated events, we ﬁrst determined the effects of func-
tional expression of TNF receptors on the ability of HD-5 to induce
cell death (Fig. 1). Cells expressing the TNF receptor 1 and 2 or cells
that do not express these receptors (KO12) were exposed to HD-5.
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Fig. 2. Cellular interactions of HD-5 depend on the cysteine-rich domain 1 of TNFR1. TNFR1&2 double-knockout murine ﬁbroblast cell lines stably expressing TNFR1-FAS,
DCRD1-TNFR1-FAS or CRD1TNFR2-TNFR1-FAS were exposed to TNFa or HD-5 alone (A) or in combination (B) at peptide concentrations of 5, 10 or 25 lg/ml and/or TNFa
concentrations of 0.1, 1 or 10 ng/ml as indicated. Data represent three experiments carried out in triplicate (⁄P 6 0.05; dP 6 0.005).
Fig. 1. Cellular interactions of HD-5 are TNF receptor-dependent. (A) Wild-type or TNF receptor 1 and 2 (KO12) murine macrophages were exposed to the peptides at
concentrations of 10, 25 or 50 lg/ml for 24 h in serum-free medium. Mitochondrial activity was measured by MTS colorimetric measurement and plotted as percentage of
untreated control cells. Data represent average of three experiments carried out in triplicate. (B) Localization of FAM-HD-5 in murine macrophages determined by confocal
microscopy. Panels show the bright ﬁeld image with the ﬂuorescence image superimposed. The ﬂuorescence images represent a 1 lM optical section acquired approximately
at the equator of the cells, which typically are 15 lM. (C) Cells were exposed to HD-5 at a concentration (25 lg/ml) for 24 h in serum-free medium. Caspase-8 activity was
determined in cellular lysates by measuring the ﬂuorescence of the Ac-VETD-AMC substrate conversion. Data represent average of three experiments carried out in sextuplet
(⁄P 6 0.05; dP 6 0.005).
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manner in wild-type murine macrophages, cell killing was
abrogated in the absence of TNF receptors (Fig. 1A). Caspase-8-
dependent apoptosis mediated via TNF receptor 1 requires recep-
tor internalization [35]. We thus examined the localization of
ﬂuorescently labeled HD-5 as well as its ability to induce caspase
activity as a function of TNF receptor expression. Wild-type and
TNFR1 and 2 knockout cells were incubated with labeled defensin
at 4 C to prevent endocytosis and peptide localization was visual-
ized by confocal microscopy after shifting the cells to 37 C
(Fig. 1B). In the absence of TNF receptor expression, HD-5remained surface-associated, whereas the peptide was readily
internalized in wild-type cells. Concomitant, HD-5 induced cas-
pase-8 activity in wild-type, but not in TNF receptor knockout cells
(Fig. 1C). HD-5 did not induce the activity of caspase-9 in either cell
line (data not shown). Thus, HD-5 mediated cell killing, internali-
zation and induction of caspase-8 activity depends on functional
TNF receptor expression.
We further examined the involvement of TNF receptors on the
cellular interactions of HD-5 in more detail. First, we tested the
possibility of interactions between HD-5 and extra-cellular do-
mains of TNF receptors. For these experiments, we used TNF
W. Lu, E. de Leeuw / FEBS Letters 588 (2014) 1906–1912 1909receptor knock-out mouse ﬁbroblast cell lines stably transfected
with the following constructs: the extra-cellular domain of TNFR1
fused to FAS (TNFR1-FAS), the extra-cellular domain of TNFR1 with
the ﬁrst cysteine-rich domain deleted (DTNFR1-FAS) and the ex-
tra-cellular domain with the cysteine-rich domain of TNFR2
replacing that of TNFR1 (CRD1TNFR2-TNFR1-FAS) [34]. These cells
were incubated in the presence of HD-5, TNFa or both at various
concentrations and effects on cell survival were determined by
MTT assays (Fig. 2). TNFa reduced cell viability in a concentra-
tion-dependent manner only of the TNFR1-FAS cell line as de-
scribed previously [34]. This is due to the observation that the
CRD1 domain of TNFR1 alters the binding afﬁnity of the receptor
for its ligand without directly interaction with TNFa [34]. Exposure
to 5 lg/ml of HD-5 did not signiﬁcantly reduced cell viability of
these three cell lines. Exposure to 10 and in particular 25 lg/ml
of HD-5 however, did reduce cell viability. HD-5 reduced cell via-
bility of all three cell lines, however cell viability was signiﬁcantly
more reduced for the TNFR1-FAS cell line compared to the two
other cell lines. The presence of 1 or 10 ng of TNFa greatly en-
hanced cell killing mediated by HD-5 of the TNFR1-FAS cell line
only, even at 5 lg/ml concentration of the defensin peptide
(Fig. 2B). Only at the highest concentrations of TNFa and HD-5
tested (10 ng and 25 lg/ml, respectively) was a reduction in cell
survival observed of the DTNFR1-FAS and CRD1TNFR2-TNFR1-FAS
cells. HD-5 was internalized by these cells (not shown).
Next, we examined the effects of TNF receptor downstream
effectors mediating signaling or cell death as measures forIL
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Fig. 3. Cellular interaction of HD-5 depends on functional expression of RIPK1 and caspas
cells were exposed to the peptides at concentrations of 5, 10 or 25 lg/ml for 24 h in
measurement and plotted as percentage of untreated control cells (B) Localization of FA
ﬁeld image with the ﬂuorescence image superimposed. The ﬂuorescence images represe
typically are 15 lM. (C) Jurkat cell lines were exposed to HD-5 (25 lg/ml) for 16 h. Int
Invitrogen. Means ± S.E.M. for three independent experiments carried out in triplicate ar
serum-free medium. Caspase-8 activity was determined in cellular lysates by measurin
experiments carried out in triplicate (⁄P 6 0.05; dP 6 0.005).involvement of TNF pathways in cellular effects of HD-5. For these
experiments, we used Jurkat cells that are deleted for the central
downstream TNF receptor kinase RIP1 (termed Jurkat TM2) or cas-
pase-8 (termed Jurkat I9.2), respectively. We determined the abil-
ity of HD-5 to mediate cell death, induce secretion of interleukin-8
and activate caspase-8 in these cells compared to wild-type Jurkat
cells (Fig. 2). We ﬁnd that HD-5 mediates cell killing of wild-type
and RIP1-deﬁcient Jurkat cells in a concentration-dependent man-
ner (Fig. 3A). Deﬁciency of caspase-8 however signiﬁcantly negated
cell killing. Deﬁciency of either caspase-8 or RIP1 did not alter the
localization of HD-5, which was found intra-cellular in all Jurkat
cells (Fig. 3B). We next examine the ability of HD-5 to induce IL-
8 secretion or activate caspase-8 by these cells (Fig. 3C and D).
Deletion of RIP1 abrogated the induction of IL-8 as well as cas-
pase-8 activity observed in wild-type Jurkat cells exposed to the
defensin. As expected, caspase-8 activity was absent in the cas-
pase-8 deﬁcient Jurkat I9.2 cells. Interestingly, IL-8 secretion by
these cells was reduced compared to wild-type cells. Again, HD-5
failed to induce caspase-9 activity in these cell lines (not shown).
Thus, HD-5 signaling and cell killing is severely diminished by deﬁ-
ciency in caspase-8. Deﬁciency of RIP1 negated induction of IL-8
secretion as well as induction of caspase-8 activity. Combined with
the ﬁndings above, these results indicate that HD-5 affects TNF
receptor activity extrinsically.
Deﬁciency in caspase-8 severely diminished, but not completely
abolished cell death mediated by HD-5 (Fig. 3A), suggesting that
the defensin kills cells via a secondary mechanism. To investigatel) 
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Fig. 5. HD-5 is a mitochondrial toxin. Wild-type and TNF receptor knockout macrophages, as well as wild-type, caspase-8- and RIPK1-deﬁcient JURKAT cells were exposed to
HD-5 at the indicated concentrations for 24 h in serum-free medium. Cell membrane integrity (A) and ATP release (B) were determined as described in Section 2. Results
shown represent three experiments carried out in triplicate.
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ﬂow cytometry. Jurkat cells deﬁcient in caspase-8, RIPK1 or
wild-type were exposed to HD-5 and apoptosis was determined
by Annexin V/Propium Iodide staining (Fig. 4). Analysis of dead
cells revealed that the majority of wild-type and RIP1-deﬁcient Jur-
kat cells were in late stage apoptosis and/or necrosis. As expected,
apoptosis was not detected in caspase-8-deﬁcient cells, and the
majority of dead cells were necrotic when exposed to HD-5
(Fig. 4, middle panel). HD-5 treated macrophages aggregated fol-
lowing de-adherence and could not reliably be analyzed by this
approach.
Since the ability of HD-5 to induce cell death correlates with its
intracellular location, we examined the possibility that the defen-
sin mediates apoptosis intrinsically by affecting the integrity of
the mitochondrial membrane. We examined the ability of HD-5
to affect mitochondrial function by measuring cellular ATP levels
and cell membrane integrity simultaneously (Fig. 5). HD-5 did
not affect cell membrane integrity of either the wild-type or TNF
receptor-deﬁcient murine macrophages. In contrast, the cell mem-
brane integrity of Jurkat cells was compromised by the defensin in
a concentration-dependent manner, irrespective of caspase-8 or
RIP1-deﬁciency (Fig. 5A). Cellular ATP levels were signiﬁcantly
and concentration-dependently reduced by HD-5 in all cell lines,
with the exception of the receptor knockout cell line (Fig. 5B).
Together, these data indicate that intracellular location of HD-5is required for mitochondrial toxicity, suggesting an intrinsic
mechanism-of-action of cell killing by the defensin, even in the ab-
sence of caspase-8.
4. Discussion
We previously reported that HD-5 acts synergistically with
TNFa [29]. Here, we show the involvement of the TNF receptors
and TNF-mediated signaling pathways in the cellular interactions
of HD-5. Tumor Necrosis Factor a is a key regulator in the immune
system with strong proinﬂammatory and immunomodulatory
properties. It is also involved in controlling life or death of target
cells and plays a critical role in many acute and chronic inﬂamma-
tory diseases [36]. TNFa can be produced by many different cell
types and exists in homo-trimeric transmembrane as well as solu-
ble forms, both biologically active. Both forms of TNFa interact
with the extracellular domain of either of two structurally distinct
receptors, TNFR1 and TNFR2, activating distinct intracellular sig-
naling pathways and gene transcription [35,37]. The extracellular
domains of TNF receptors are comprised of 3–4 cysteine-rich do-
mains or CRDs. Trimers of receptor chains pre-assemble on the cell
surface prior to ligand binding, owing to associations of the pre-
ligand–binding assembly domain or PLAD [38]. These PLAD
domains comprise of the ﬁrst CRD domain plus an unstructured
N-terminal sequence and are subtype-speciﬁc for TNF receptors.
W. Lu, E. de Leeuw / FEBS Letters 588 (2014) 1906–1912 1911Native formation of ligand-independent trimers is necessary for li-
gand binding and death signaling [38,39]. TNFR1 is expressed con-
stitutively on almost every type of cell in the body except
erythrocytes, whereas TNRF2 expression is generally inducible
and more limited to endothelial cells and hematopoietic cells pref-
erentially [40]. Although soluble TNFa binds to both receptors, it
preferentially binds to TNFR1, whereas the trans-membrane form
binds preferentially to TNFR2 [41,42].
TNFR1 is capable of inducing cell death or anti-apoptotic signal-
ing via NF-jB or MAPK pathways. TNFR1 receptor internalization is
essential for transmitting the signals that lead to apoptosis [43].
Signaling initiated by soluble TNF via TNFR1 and TNFR2 is medi-
ated by adapter proteins that bind to the cytoplasmic domains of
the receptors upon extracellular ligand binding. The cytoplasmic
region of TNFR1 contains a death domain that couples TNFR1 to
either of 2 distinct signaling pathways via binding of the adapter
protein TNFR-associated death domain. The primary pathway leads
to activation of nuclear factor kappa-B1 (NF-jB1), a family of tran-
scription factors that control a large number of inﬂammatory
genes, and a distinct signaling pathway leads to caspase-8- and
caspase-3-dependent apoptosis. TNFR2 signaling generally pro-
motes NF-jB1-dependent transcription of pro-survival genes
[40]. Cross-talk between signaling pathways of TNFR1 and TNFR2
further determines the balance between cell death and survival
[40].
We ﬁnd that HD-5 interacts with the extra-cellular domain of
TNF receptors. This interaction depended on the presence of the
ﬁrst cysteine-rich domain of TNFR1, a domain that does not di-
rectly bind to ligand, but does affect ligand binding afﬁnity [34].
We further ﬁnd that HD-5 exerts signaling and apoptotic events
associated with those of TNF receptor 1 [35]: (1) HD-5 induces cas-
pase-8 activity only upon internalization; (2) HD-5 signaling and
caspase-8 activation is a RIP1-dependent; (3) deletion of the
CRD1 domain of TNFR1 or its replacement with the CRD1 domain
of TNFR2 signiﬁcantly reduces cell-mediated killing by HD-5. Com-
bined, these observations together with previously observed HD-5
signaling [30] and synergism of HD-5 and TNFa [29], our data sug-
gest interactions between HD-5 and TNFR1. In addition, we ﬁnd
that HD-5 depolarizes the mitochondrial membrane only upon
internalization. Mitochondrial membrane activity was observed
in the absence of functional RIP1, and further, HD-5 did not induce
caspase-9 activity. These ﬁndings indicate that, once inside the cell,
the antimicrobial defensin peptide HD-5 kills the cells via a second
mechanism, likely by directly targeting the bacterial-derived mito-
chondrial membrane.
A speciﬁc deﬁciency of HD-5 has been observed in patients with
ileal Crohn’s disease, a chronic inﬂammatory disease [44,45]. These
ﬁndings have led to the notion that HD-5 as an innate immune
effector molecule may play an important role in the maintenance
of mucosal balance and that deﬁciency of HD-5, resulting in weak-
ening of mucosal antibacterial capacity may contribute to patho-
genesis [46]. Based on our ﬁndings, HD-5 may play additional
roles in regulating cell death and differentiation by directly and
speciﬁcally acting on cells of the host also. Interestingly, expression
of both TNFa as well as defensins locates exclusively to Paneth cell
granules in mice and humans in normal bowel [47,48].
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